Form 4: QuidelOrtho Director Evelyn Dilsaver Receives Equity Grant of 6,829 Restricted Stock Units

QuidelOrtho Corp (QDEL) Director Evelyn S. Dilsaver was granted 6,829 restricted stock units (RSUs) on May 29, 2025, aligning her interests with shareholders.

Summary

• Evelyn S. Dilsaver, a Director of QuidelOrtho Corp (QDEL), received an equity grant of 6,829 Restricted Stock Units (RSUs).
• The transaction date for this grant was May 29, 2025.
• Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
• These restricted stock units will vest on May 29, 2026.
• Following this transaction, Evelyn S. Dilsaver beneficially owns 6,829 derivative securities (RSUs) directly.

Sentiment

Score: 7

Explanation: The sentiment is positive as it indicates a routine equity grant to a director, which aligns management's interests with shareholders and is a standard practice for incentivizing long-term commitment and performance. There are no negative implications from this specific filing.

Positives

• The grant of restricted stock units to a director helps align the director's financial interests with those of the company's shareholders, incentivizing long-term performance.
• Equity compensation is a common practice for retaining and motivating key personnel and board members.

Future Outlook

The restricted stock units are scheduled to vest on May 29, 2026, indicating a future conversion to common stock for the reporting person.

Management Comments

• The filing indicates that the transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

Equity grants, such as Restricted Stock Units, are a standard component of executive and director compensation packages across various industries, including the healthcare diagnostics sector where QuidelOrtho operates. They are designed to align the interests of company leadership with long-term shareholder value creation.

Comparison to Industry Standards

• The granting of Restricted Stock Units to board members is a common compensation practice in publicly traded companies, including those in the medical diagnostics and biotechnology sectors, such as Abbott Laboratories, Danaher Corporation, and Thermo Fisher Scientific, which frequently use equity awards to incentivize and retain directors.
• The specific number of units granted would typically be benchmarked against peer group compensation data, considering the company's size, performance, and the director's role and tenure, though this filing does not provide such comparative details.

Related Party Transactions

• This filing details an equity grant from QuidelOrtho Corp to Evelyn S. Dilsaver, a Director of the company, which is considered an insider transaction.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with shareholder value creation, potentially leading to better long-term performance.
• Employees: While not directly impacting general employees, such grants are part of a broader compensation philosophy that can influence overall company culture and retention strategies for key personnel.

Next Steps

• The Restricted Stock Units are scheduled to vest on May 29, 2026, at which point they will convert into shares of QuidelOrtho Corporation common stock.

Key Dates

Keywords

QuidelOrtho Corp, QDEL, Restricted Stock Units, RSU, Equity Grant, Insider Transaction, SEC Form 4, Director Compensation, Executive Compensation